Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close.

The S&P 500 tumbled to a six-month low Thursday amid fresh Trump tariff threats. Tesla stock fell amid a new report on its upcoming "affordable" EV. Warren Buffett's Berkshire rose within a buy zone.

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Hartford Healthcare Fund (I share) underperformed the S&P Composite 1500 Health Care Index during the quarter. The S&P Composite 1500 Health Care Index declined -9.82% during the quarter ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

VRTX’s POWR Ratings reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio's top stock picks. The American quant ...